NASDAQ:MLTX MoonLake Immunotherapeutics (MLTX) Stock Price, News & Analysis $10.41 -0.27 (-2.53%) Closing price 10/13/2026 04:00 PM EasternExtended Trading$10.36 -0.05 (-0.53%) As of 07:24 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About MoonLake Immunotherapeutics Stock (NASDAQ:MLTX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get MLTX alerts:Sign Up Key Stats Today's Range$10.36▼$10.8450-Day Range$10.41▼$18.2652-Week Range$8.80▼$23.29Volume2.41 million shsAverage Volume1.99 million shsMarket Capitalization$886.00 millionP/E RatioN/ADividend YieldN/APrice Target$28.50Consensus RatingHold Company Overview MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company focused on developing medicines for inflammatory and immunologic diseases. The company is headquartered in Zug, Switzerland, and its ordinary shares trade on the Nasdaq under the symbol MLTX. MoonLake’s primary product candidate is sonelokimab, a novel Nanobody-based inhibitor designed to selectively target interleukin-17A and interleukin-17F, two cytokines involved in inflammation. The company is evaluating sonelokimab in conditions including hidradenitis suppurativa, psoriatic arthritis and axial spondyloarthritis, with the goal of addressing significant unmet needs in chronic inflammatory disease. MoonLake was established to advance sonelokimab and related immunology programs and has developed its business around a Nanobody-based drug-development platform. The company’s activities are focused primarily on clinical development and regulatory preparation rather than commercialized products, and its programs are intended for patients in international markets where inflammatory diseases are prevalent.AI Generated. May Contain Errors. Read More MoonLake Immunotherapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks58th Percentile Overall ScoreMLTX MarketRank™: 2.89866560972 of 5 starsMoonLake Immunotherapeutics scored higher than 58% of companies evaluated by MarketBeat, and ranked 517th out of 877 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.8 / 5Analyst RatingHold Consensus RatingMoonLake Immunotherapeutics has received a consensus rating of Hold. The company's average rating score is 2.43, and is based on no strong buy ratings, 9 buy ratings, 2 hold ratings, and 3 sell ratings.Upside PotentialMoonLake Immunotherapeutics has a consensus price target of $28.50, representing about 173.8% upside from its current price of $10.41.Amount of Analyst CoverageMoonLake Immunotherapeutics has only been the subject of 3 research reports in the past 90 days.Read more about MoonLake Immunotherapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for MoonLake Immunotherapeutics are expected to decrease in the coming year, from ($3.34) to ($3.41) per share.Price to Book Value per Share RatioMoonLake Immunotherapeutics has a P/B Ratio of 2.44. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about MoonLake Immunotherapeutics' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted10.55% of the float of MoonLake Immunotherapeutics has been sold short.Short Interest Ratio / Days to CoverMoonLake Immunotherapeutics has a short interest ratio ("days to cover") of 4.23.Change versus previous monthShort interest in MoonLake Immunotherapeutics has recently decreased by 10.05%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMoonLake Immunotherapeutics does not currently pay a dividend.Dividend GrowthMoonLake Immunotherapeutics does not have a long track record of dividend growth. News and Social Media3.2 / 5News Sentiment1.10 News SentimentMoonLake Immunotherapeutics has a news sentiment score of 1.10. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.70 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 2 news articles for MoonLake Immunotherapeutics this week, compared to 10 articles on an average week.Search InterestOnly 3 people have searched for MLTX on MarketBeat in the last 30 days. This is a decrease of -25% compared to the previous 30 days.MarketBeat Follows2 people have added MoonLake Immunotherapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership1.8 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, MoonLake Immunotherapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,900,933.00 in company stock.Percentage Held by Insiders10.40% of the stock of MoonLake Immunotherapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions93.85% of the stock of MoonLake Immunotherapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about MoonLake Immunotherapeutics' insider trading history. Receive MLTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for MoonLake Immunotherapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. MLTX Stock News HeadlinesMoonLake Immunotherapeutics (MLTX) Receives a Rating Update from a Top AnalystOctober 8, 2026 | theglobeandmail.comMoonLake Immunotherapeutics (NASDAQ:MLTX) Given "Buy" Rating at HC WainwrightOctober 5, 2026 | americanbankingnews.comWall Street legend reveals his top AI stock before Oct. 20Marc Chaikin, the 60-year Wall Street veteran behind the Power Gauge rating system, has flagged a new AI stock ahead of October 20. His system has spotted at least seven of the top 10 performers every year since 2016, including all ten in the 2022 bear market and every member of the Magnificent Seven before their run higher. Now Chaikin's Power Gauge is turning bullish on an under-the-radar company tied to next-generation AI data centers built under Executive Order 14363, technology he says uses 99 percent less electricity and space while offering far greater computing power.October 14 at 1:00 AM | Chaikin Analytics (Ad)Analysts’ Opinions Are Mixed on These Healthcare Stocks: MoonLake Immunotherapeutics (MLTX) and Liquidia Technologies (LQDA)October 2, 2026 | theglobeandmail.comMoonLake files FDA application for sonelokimab therapySeptember 30, 2026 | tipranks.comMLTX stock on track for worst week since last fall as FDA filing date for skin disease drug draws nearSeptember 11, 2026 | msn.comMoonLake Immunotherapeutics: The Bull Case Does Not Require Clinical SupremacySeptember 8, 2026 | seekingalpha.comMoonLake Immunotherapeutics (MLTX)August 23, 2026 | finance.yahoo.comSee More Headlines MLTX Stock Analysis - Frequently Asked Questions How have MLTX shares performed this year? MoonLake Immunotherapeutics' stock was trading at $13.18 at the start of the year. Since then, MLTX shares have decreased by 21.0% and is now trading at $10.41. How were MoonLake Immunotherapeutics' earnings last quarter? MoonLake Immunotherapeutics (NASDAQ:MLTX) announced its earnings results on Monday, August, 10th. The company reported ($0.84) EPS for the quarter, beating analysts' consensus estimates of ($0.91) by $0.07. When did MoonLake Immunotherapeutics IPO? MoonLake Immunotherapeutics (MLTX) raised $100 million in an initial public offering (IPO) on Tuesday, October 20th 2020. The company issued 10,000,000 shares at a price of $10.00 per share. Who are MoonLake Immunotherapeutics' major shareholders? MoonLake Immunotherapeutics' top institutional shareholders include Congress Asset Management Co. (0.26%). Insiders that own company stock include Da Silva Jorge Santos, Kristian Reich, Bvf Partners L P/Il, Matthias Bodenstedt and Simon Sturge. View institutional ownership trends. How do I buy shares of MoonLake Immunotherapeutics? Shares of MLTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of MoonLake Immunotherapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that MoonLake Immunotherapeutics investors own include Palantir Technologies (PLTR), Advanced Micro Devices (AMD), Intel (INTC), Rocket Lab (RKLB), SoundHound AI (SOUN), Archer Aviation (ACHR) and Eli Lilly and Company (LLY). Company Calendar Last Earnings8/10/2026Today10/14/2026Next Earnings (Estimated)11/04/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (1w+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 For the last 8 days, MLTX's financial health has been in the Red zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:MLTX CIK1821586 Webwww.moonlaketx.com Phone41-41-510-8022FaxN/AEmployees130Year FoundedN/APrice Target and Rating Average Price Target for MoonLake Immunotherapeutics$28.50 High Price Target$50.00 Low Price Target$10.00 Potential Upside/Downside+173.8%Consensus RatingHold Rating Score (0-4)2.43 Research Coverage14 Analysts Profitability EPS (Trailing Twelve Months)($3.84) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$227.32 million Net MarginsN/A Pretax MarginN/A Return on Equity-82.53% Return on Assets-58.17% Debt Debt-to-Equity Ratio0.23 Current Ratio12.56 Quick Ratio12.56 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.27 per share Price / Book2.44Miscellaneous Outstanding Shares85,110,000Free Float76,256,000Market Cap$886.00 million OptionableOptionable Beta1.08 Don't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free Report This page (NASDAQ:MLTX) was last updated on 10/13/2026 by MarketBeat.com Staff. From Our PartnersElon Musk’s One Stock Retirement PlanJeff Brown picked Nvidia in 2016, before it surged 37,000 percent. Now he's tracking a small AI company he say...Brownstone Research | SponsoredTrump's about to unleash his Midterm WeaponTrump is turning the midterms into a referendum on American energy, pushing for more oil, more gas, and lower ...Monument Traders Alliance | SponsoredWall Street legend reveals his top AI stock before Oct. 20Marc Chaikin, the 60-year Wall Street veteran behind the Power Gauge rating system, has flagged a new AI stock...Chaikin Analytics | SponsoredA Simple Guide to Options Trading While It's Still FreeA free copy of Options Trading Made Simple is available now but wont stay that way for long. Chris Rowe cal...True Market Insiders | SponsoredFederal Reserve Reveals Disturbing New Plan To Control Your MoneyDocket No. OP-1670 is drawing attention for what it reveals about the Federal Reserve's next move. Buried on p...Weiss Ratings | SponsoredThis AI fund posted a 34 percent annualized payout last monthOne small fund tied to artificial intelligence stocks delivered $1,051 in a single month, not through selling ...Investors Alley | SponsoredI'm giving you a space stock today. Free.On December 8th, $600 billion in frozen SpaceX stock comes loose. Dylan Jovine says one simple purchase in any...Behind the Markets | SponsoredA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MoonLake Immunotherapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Share MoonLake Immunotherapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
